Artemether in the treatment of Fasciola hepatica and/or Fasciola gigantica infections in Egypt

Completed

• Conditions: Fascioliasis; Infections and Infestations; Other fluke infections

• Registration Number: ISRCTN10372301
• Lead Sponsor: Swiss Tropical Institute (Switzerland)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-03-30
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Both males and females, age 11-70 years
2. For married females, not pregnant, as assessed by the medical doctor last menstrual cycle, upon initial clinical assessment
3. Absence of major systemic illnesses, as assessed by the medical doctor, upon initial clinical assessment
4. Infection with F. hepatica and/or F. gigantica as confirmed by standard parasitological stool examination
5. No known or reported hypersensitivity to artemether
6. No known or reported history of chronical illness such as cancer, diabetes, hypertension, chronic heart, liver or renal disease
7. Full clinical examination
8. Written informed consent

Exclusion Criteria

1. Presence of any abnormal medical condition, judged by the medical doctor. If several patients experience serious adverse events the study will be stopped.
2. Severe liver disease of other aetiology
3. Recent history of anthelminthic drugs (triclabendazole, albendazole, bithionol, dehydroemetine, praziquantel within past 4 weeks)
4. Attending other clinical trials during the study
5. For females: pregnancy, lactation

Study & Design

• Study Type: Interventional
• Study Design: Not specified